Next Article in Journal
Effect of Stabilizers on Encapsulation Efficiency and Release Behavior of Exenatide-Loaded PLGA Microsphere Prepared by the W/O/W Solvent Evaporation Method
Previous Article in Journal
A Novel Rheological Method to Assess Drug-Polymer Interactions Regarding Miscibility and Crystallization of Drug in Amorphous Solid Dispersions for Oral Drug Delivery
Article

Repeat-Dose Toxicity Study Using the AFPL1-Conjugate Nicotine Vaccine in Male Sprague Dawley Rats

1
Finlay Institute of Vaccine, Havana 11600, Cuba
2
Health Sciences North Research Institute (HSNRI), Sudbury, ON P3E 2H3, Canada
3
Northern Ontario School of Medicine (NOSM), Laurentian University, Sudbury, ON P3E 2C6, Canada
4
Chemistry & Biochemistry and Biology Departments, Laurentian University, Sudbury, ON P3E 2C6, Canada
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Pharmaceutics 2019, 11(12), 626; https://doi.org/10.3390/pharmaceutics11120626
Received: 28 August 2019 / Revised: 15 November 2019 / Accepted: 20 November 2019 / Published: 23 November 2019
Tobacco smoking is the cause of 20% of Canadian deaths per year. Nicotine vaccines present a promising alternative to traditional smoking cessation products, but to date, no vaccine has been able to move through all phases of clinical trials. We have previously demonstrated that the AFPL1-conjugate nicotine vaccine does not induce systemic or immunotoxicity in a mouse model and that a heterologous vaccination approach is more advantageous than the homologous routes to inducing mucosal and systemic anti-nicotine antibodies. The purpose of this study was to confirm the safety profile of the vaccine in a repeat-dose toxicity study. The heterologous vaccination strategy was again used, and Sprague Dawley rats were administered a dose five times greater than in our previous studies. Physiological conditions, food and water consumption, body temperature, injection site inflammation, relative weights of organs, histopathology, and blood chemistry and hematology were evaluated during the course of the vaccination period to determine the safety of the vaccine. The AFPL1-conjugate nicotine vaccine did not induce clinically relevant changes or induce symptoms that would be associated with toxicity, making it a promising candidate for future investigations. View Full-Text
Keywords: nicotine vaccine; AFPL1 adjuvant; repeat-dose toxicity; heterologous administration nicotine vaccine; AFPL1 adjuvant; repeat-dose toxicity; heterologous administration
Show Figures

Graphical abstract

MDPI and ACS Style

Oliva, R.; Fraleigh, N.L.; Lewicky, J.D.; Fariñas, M.; Hernández, T.; Martel, A.L.; Navarro, I.; Dagmar, G.-R.; Acevedo, R.; Le, H.-T. Repeat-Dose Toxicity Study Using the AFPL1-Conjugate Nicotine Vaccine in Male Sprague Dawley Rats. Pharmaceutics 2019, 11, 626. https://doi.org/10.3390/pharmaceutics11120626

AMA Style

Oliva R, Fraleigh NL, Lewicky JD, Fariñas M, Hernández T, Martel AL, Navarro I, Dagmar G-R, Acevedo R, Le H-T. Repeat-Dose Toxicity Study Using the AFPL1-Conjugate Nicotine Vaccine in Male Sprague Dawley Rats. Pharmaceutics. 2019; 11(12):626. https://doi.org/10.3390/pharmaceutics11120626

Chicago/Turabian Style

Oliva, Reynaldo; Fraleigh, Nya L.; Lewicky, Jordan D.; Fariñas, Mildrey; Hernández, Tamara; Martel, Alexandrine L.; Navarro, Ingrid; Dagmar, García-Rivera; Acevedo, Reinaldo; Le, Hoang-Thanh. 2019. "Repeat-Dose Toxicity Study Using the AFPL1-Conjugate Nicotine Vaccine in Male Sprague Dawley Rats" Pharmaceutics 11, no. 12: 626. https://doi.org/10.3390/pharmaceutics11120626

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop